Nectar Lifesciences completes slump and asset sales

Nectar Lifesciences Limited announced the completion of its slump sale and asset sale on November 10, 2025, as per an intimation to the National Stock Exchange and BSE dated November 13, 2025. This transaction involved a business transfer agreement (BTA) and an asset purchase agreement (APA) executed with Ceph Lifesciences Private Limited on July 07, 2025.

The final consideration for the BTA has been determined to be INR 1253.99 crore, incorporating working capital adjustments as specified in the agreement.

Additionally, the final consideration for the APA remained consistent with the earlier disclosure, amounting to INR 20.00 crore. This update confirms the successful conclusion of both components of the transaction.